Virometix delops a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases. The startup was founded 2009 by Arin Ghasparian and Nina Huwiler who left the company in 2012.
Anna Sumeray who now takes over as CEO brings more than 25 years of business leadership in the pharmaceutical and biotechnology industries. Ms. Sumeray currently serves as Managing Partner of Alacrita, a global life science consulting firm where she is responsible for the European operations and Commercial Practice. Ms. Sumeray began her career in the life science industry at Amgen in business analysis and strategic planning, and moved to Novartis where she progressed through successive positions of increasing responsibility, including Head of Novartis Ophthalmics Global Business Development and Licensing and roles with P&L responsibility at Novartis Oncology in Finland, Novartis Oncology Germany and Nephrology and Transplantation at Sandoz. She is also the owner of BioVault, an investment and consultancy company for start-up biotech companies and has been advising management of and making private investments in early-stage ventures for over 20 years.
Pierre Morgon, Chairman of the Board of Directors of Virometix commented: “We are delighted to welcome Anna as Chief Executive Officer of Virometix. Her 25 years’ of diverse experience across diverse types of organizations and her track record of developing international businesses will be key advantages for the expansion of Virometix.”
Anna Sumeray, incoming Chief Executive Officer of Virometix, added, “I am joining the Virometix team with great enthusiasm and look forward to contributing my skills and experience to the advancement of the Virometix development activities and international partnering.”